4 Common AEs may include, but are not limited to: cough, respiratory issues, diarrhea, constipation, pain, sweating, headache, confusion, jaundice, seizures, sensitivity to light, weight changes, alopecia or hirsutism, tachycardia, hepatomegaly, and splenomegaly
Clinical studies have shown that participants can lose an average of 10% to 15% of their initial body weight over a 68-week period, with successful results often tied to lifestyle changes such as a healthy diet and regular exercise
Hsp72 preserves muscle function and slows progression of severe muscular dystrophy
2012 Jul 1
2 Key Players In The GLP-1 Market Novo Nordisk Positioning: Novo Nordisk (Novo) is the undisputed leader in the GLP-1 receptor agonist market, largely due to the success of semaglutide, which is marketed as Ozempic for diabetes and Wegovy for weight management
Endoplasmic reticulum-mitochondrial calcium transport contributes to soft extracellular matrix-triggered mitochondrial dynamics and mitophagy in breast carcinoma cells
